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T
he meeting was launched with an
introductory keynote address by
Peixuan Guo (University of Cincinnati),
the chair of the organizing committee. Dr. Guo
introduced the topic of RNA nanotechnol-
ogy, its history, approaches, current status,
and future prospects, emphasizing that liv-
ing organisms possess a wide variety of
natural nanomachines, elegantly patterned
arrays, and highly ordered structures per-
forming diverse biological functions. There
are numerous intriguing conﬁgurations that
have inspired biomimetic stategies. He
noted that macromolecules of DNA, RNA,
and proteins have intrinsically deﬁned fea-
tures at the nanometer scale and can serve
as powerful building blocks for bottom-up
fabrication of nanostructures. The rapid ad-
vances in DNA nanotechnology have
created unexpected bridges between ma-
terial engineering and synthetic structural
biology.13 Dr. Guo emphasized that the
ﬁeld of RNA nanotechnology is new and
rapidly emerging. Over the last ﬁve years,
there has been a burst of publications on
RNA nanostructures, indicating increasing
interest in RNA nanotechnologies in
diverse ﬁelds such as microbiology, bio-
chemistry, biophysics, chemistry, struc-
tural biology, nanomedicine, and cell
biology. RNA-based nanoscaﬀolds are
therefore expected to have great impact
in the near future especially with regard to
diagnostics and therapeutics.4
Guo noted that RNA, as a cousin of DNA,
has recently emerged as an important nano-
technology platform due to its extraor-
dinary diversity in structure and function.
RNA nanoparticles can be fabricated with a
level of simplicity characteristic of DNA, plus
they possess versatile tertiary structure and
catalytic functions that can mimic some
forms of proteins.58 RNA is unique in
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ABSTRACT This Nano Focus article highlights recent advances in RNA nanotechnology as presented at
the First International Conference of RNA Nanotechnology and Therapeutics, which took place in Cleveland,
OH, USA (October 2325, 2010) (http://www.eng.uc.edu/nanomedicine/RNA2010/), chaired by Peixuan
Guo and co-chaired by David Rueda and Scott Tenenbaum. The conference was the ﬁrst of its kind to bring
together more than 30 invited speakers in the frontier of RNA nanotechnology from France, Sweden, South
Korea, China, and throughout the United States to discuss RNA nanotechnology and its applications. It
provided a platform for researchers from academia, government, and the pharmaceutical industry to share
existing knowledge, vision, technology, and challenges in the ﬁeld and promoted collaborations among
researchers interested in advancing this emerging scientiﬁc discipline. The meeting covered a range of
topics, including biophysical and single-molecule approaches for characterization of RNA nanostructures;
structure studies on RNA nanoparticles by chemical or biochemical approaches, computation, prediction,
andmodeling of RNA nanoparticle structures; methods for the assembly of RNA nanoparticles; chemistry for
RNA synthesis, conjugation, and labeling; and application of RNA nanoparticles in therapeutics. A special
invited talk on the well-established principles of DNA nanotechnology was arranged to provide models for
RNA nanotechnology. An Administrator from National Institutes of Health (NIH) National Cancer Institute
(NCI) Alliance for Nanotechnology in Cancer discussed the current nanocancer research directions and future
funding opportunities at NCI. As indicated by the feedback received from the invited speakers and the
meeting participants, this meeting was extremely successful, exciting, and informative, covering many
groundbreaking ﬁndings, pioneering ideas, and novel discoveries.
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comparison to DNA by virtue of its
high thermodynamic stability,9,10 the
formation of both canonical and
noncanonical base pairings,1115 the
capability of base stacking,9,10 and
distinctive in vivo attributes.1623
The remarkable modularity of RNA
tertiary motifs can be encoded at
the level of an RNA sequence to
specify complex three-dimensional
(3D) architectures exhibiting helices,
loops, bulges, stems, hairpins, and
pseudoknots. Further, a large variety
of single-stranded loops are suitable
for inter- and intramolecular inter-
actions, serving as amounting dove-
tail in self-assembly. Taking advan-
tage of these unique characteristics,
Dr. Guo presented highlights from
his pioneering work in 1998, which
demonstrated that RNA dimer, tri-
mer, and hexamer nanopaticles can
be fabricated by re-engineering RNA
molecules using themodel of motor
pRNA (packaging RNA), a compo-
nent that gears the DNA packaging
motor of bacteriophage phi29.22 He
showed that the pRNA can be used
as a building block or scaﬀold for
constructing a variety of RNA nano-
structures with functional entities as
delivery vehicles or imaging tools.
He further described the application
of RNA nanomotors in various as-
pects of cellular and molecular biol-
ogy as a tool for potential thera-
peutics. He pointed out that the
sensitivity of RNA to RNase degrada-
tion has previously made many
scientists shy away from RNA nano-
technology. The demonstration that
RNA nanoparticles can be produced
to drive viral DNA packagingmotors
using chemically modiﬁed RNA sug-
gests that it is possible to produce
RNase-resistant, biologically active,
and stable RNA for applications in
nanotechnology.24 Dr. Guo also dis-
cussed the signiﬁcant contributions
of Dr. Eric Westhoﬀ, Dr. Neocles
Leontis, and Dr. Luc Jaeger for their
fundamental structural studies of
RNA motifs and important contribu-
tions to RNA technology.13,2528
Lastly, Dr. Guo summarized the
key approaches in RNA nanoparti-
cles construction4 starting with the
conception step, whereby the de-
sired properties of the nanoparticles
are deﬁned and the global structure
of the particle and application are
considered. A computational ap-
proach is then applied to predict
the folding of the building blocks
and the consequences of inter-RNA
interactions in the assembly of the
ﬁnal RNA quaternary structure. The
building blocks are then generated
(in vitro transcription or chemical
synthesis), and the individual subu-
nits are assembled (templated or
nontemplated) into quaternary ar-
chitectures. The resulting RNA nano-
particles are characterized by the
atomic force microscope (AFM),
electron microscope (EM), gel elec-
trophoresis, chromatography, or
ﬂuorescence experiments to ensure
proper folding that is consistent
with the desired structural and func-
tional capabilities. After thorough
assessment, RNA nanoparticles are
used for a variety of applica-
tions including the treatment and
diagnosis of diseases and the regu-
lation of cellular functions. We have
arranged the following sections of
this article to match the six steps of
RNA nanoparticle construction, which
served as the overarching themes of
the meeting (Figure 1).
RNA Structures for Nanoparticle Con-
struction. RNA typically contains various
single-stranded loops that interact to
form 3D biologically important RNA
structures via inter- and intramolecular
interactions. Severalnaturallyoccurring
diverse RNA loops and motifs with
defined 3D architectures exist that
can serve as structural scaffolds in
RNA nanotechnology. One such exam-
ple is based on the structural features
of the pRNA of the bacteriophage
phi29 DNA packaging motor,22,29
which uses a hexameric RNA ring to
Figure 1. Approaches in RNA nanotechnology. Figure modiﬁed with permission
from ref 4. Copyright 2010 Nature Publishing Group.
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gear themachine.30,31Dr. Guo's group
has extensively re-engineered pRNA
to form dimers, trimers, tetramers,
hexamers (with proteins), and arrays
viahand-in-hand or foot-to-foot inter-
actions between two interlocking
loops.32,33 Thedimer and trimer nano-
particles have been used successfully
as polyvalent vehicles to deliver a
variety of therapeutic molecules32,33
as well as for constructing RNA arrays
(Figure 2).32
In his keynote address, Luc Jaeger
(University of California, Santa
Barbara) described two comple-
mentary approaches for the design
and engineering of versatile, pro-
grammable, 3D RNA-based nano-
scaﬀolds with precise control over
their geometry, size, and composi-
tion and possibility of further func-
tionalization. The ﬁrst approach
takes advantage of known RNA
structural elements. This approach,
called “RNA architectonics”, achieves
a remarkable degree of structural
control by using prefolded RNA struc-
tural motifs as building blocks for
bottom-up assemblies.3437 This
strategy is based on the rational de-
sign of artiﬁcial 3D RNA architectures
that are formed by inverse folding
processes. The second approach,
based only on canonical Watson
Crick interactions, utilizes relatively
short (2648 nt) single-stranded
RNAs. This approach employs compu-
ter-aided techniques to engineer
3D RNA, RNA/DNA, and DNA nano-
scaﬀolds.38 His group, in collaboration
with Bruce Shapiro (National Cancer
Institute), developed a range of stra-
tegies for obtaining self-assembling
RNA architectures with unprece-
dented control and precise position-
ingof functional groups in space, such
as3DRNAnanocubic scaﬀolds,38 tRNA
polyhedrons,39 and nanorings.34
Another approach in RNA nano-
particle construction is to utilize ex-
isting RNA structures with known
functions as building blocks. Within
the cell, there exist small RNAs, such
as riboswitches with regulatory func-
tions.4043 Herve Isambert's group
(Institut CurieCenter de Recherche,
France) developed pioneering experi-
mental and computational approaches
for the development of small regu-
latory circuits based mainly on RNA
interactions.44 In addition, he pre-
sented a speciﬁc example of a small
bacterial regulatory RNA, DsrA,
which self-assembles into long ﬁla-
mentous-like structures, as well as
more extended 2D/3D nanostructures
with unique switching properties.45
This important ﬁnding suggests novel
self-assemblyprinciples todesignRNA
nanoparticles with structural switch-
ing capabilities. An online RNA folding
server (http://kinefold.curie.fr) has
more than 40000 RNA folding simula-
tion studies available.
In related work, Li Niu (State Uni-
versity of New York, Albany) pre-
sented an exciting structural fold-
ing property of an RNA aptamer
sequence (identiﬁed by SELEX), which
can assume two diﬀerent structures
withdiﬀerent functions. The twostruc-
tures assemble during transcription
and act collaboratively to inhibit the
expression of GluR2, one of the gluta-
mate ion channel receptor subunits.46
The results highlight the adaptive
nature of native RNA molecules to
assume alternative stable structures
with diﬀerent functions.
Nuclearmagnetic resonance (NMR)
studies can elucidate the 3D struc-
ture of RNA motifs based on
sequence. Recently, the NMR struc-
ture of a piece of the pRNA com-
ponent (E-loop) was reported.47
Thomas Leeper's group (University
of Akron) also presented solution
NMR analysis on the Ku motif de-
rived from the telomerase RNA com-
ponent, which is a highly ﬂexible
scaﬀold that recruits multiple pro-
tein components.48 Such architec-
tural motifs can potentially be used
for designing multifunctional RNA
nanoparticles.
Importing from DNA Nanoarchitec-
tures. Since DNA and RNA share
some common structural and che-
mical features, a special seminar on
the well-established principles of
DNA nanotechnology (for recent
Figure 2. Role of phi29 DNA packaging RNA (pRNA) in RNA nanotechnology. Six
pRNA assemble into a hexameric ring to gear the DNA translocating machine. pRNA
monomers can be re-engineered to fold intowell-deﬁned structures, such as dimers,
hexamers, and arrays via hand-in-hand or foot-to-foot interactions between two
interlocking loops. pRNA-based nanoparticles have been successfully constructed
with functional modules and used as polyvalent vehicles to deliver a variety of
therapeutic/detection molecules to cancer- and viral-infected cells. Image courtesy
of YinYin Guo. Figure adaptedwithpermission from ref 136. Copyright 2011Elsevier.
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reviews, see refs 13) was arranged
to provide viable models for the
developing RNA nanotechnology
community. DNA self-assembly is
programmable and complex nano-
structures and patterns can be cre-
ated with full addressability. DNA-
directed self-assembly is an efficient
and precise way to organize nano-
materials on a molecular level, as
demonstrated elegantly by branched
DNA tiles, tensegrity triangles (rigid
structures in perioidic array form),49
algorithmic self-assembled Sierpinski
triangles (aperiodic arrays of fractal
patterns),50 nanotubes, helix bun-
dles,51 polycatenated DNA lad-
ders,52 and 3D cubes, polyhedrons,
prisms, and buckyballs.3,53
A striking demonstration of the
addressable and programmable pro-
perties of DNA is Paul Rothemund's
DNA origami.54 More recently,
Yan Liu's group (Arizona State
University) in collaboration with
Hao Yan's group (Arizona State
University) was able to use DNA to
build a reconﬁgurable M€obius strip
(topological surface with only one
side and only one boundary) based
on DNA fold-and-cut methodology
(DNA kirigami).55 Catenane (inter-
locking ring-like structures) was as-
sembled eﬃciently without enzy-
matic ligation. In other work, the
two groups in collaboration with
William Shih's group (Harvard
University) were able to design and
constructmultilayered, 3DDNAnano-
structures (DNA helices packed on
square-lattice geometries) using the
scaﬀolded-DNA-origami strategy
process.56 Their goal is to utilize
programmable, 3D DNA nano-
assemblies to direct the assembly of
materials, such as proteins arrays, as a
tool in proteomics, crystallography,
and bioagent screening processes.
Although the folding properties
of RNA and DNA diﬀer to some
degree, the fundamental principles
in DNA nanotechnology are applic-
able to RNA nanotechnology. The
use of three-way junctions (3WJ)
and four-way junctions (4WJ)13,37
to build novel and diverse RNA ar-
chitectures is very similar to the
branching approaches in DNA.1,3
Both RNA and DNA polymers can
be developed into bundles32,45,57
and jigsaw puzzles.36,58
RNA Computation and Modeling. Un-
like DNA, RNA molecules display
diverse structures mediated by both
canonical and noncanonical base
pairing and further stabilized by ter-
tiary interactions, pseudoknots, kis-
sing loops, stem stacking, etc. The
use of computationalmethodologies
can significantly lessen the time and
expense required to bring the design
of RNA-based nanoconstructs to ex-
perimental fruition. However, pre-
diction of RNA structure or fold-
ing for particle assembly remains a
great challenge, due to the unusual
folding properties involving non-
canonical interactions. Single base
modifications can result in folding
alterations and functional loss. Cur-
rently, using the RNA two-dimen-
sional (2D) prediction program by
Zuker, typically only 70% of the 2D
folding prediction is accurate based
on experimental data.59,60 Clearly,
predicting the RNA 3D and 4D struc-
tures is even more elusive. Over
the past decade, several groups
have developed computational al-
gorithms to predict the secondary
and tertiary structures of RNA.
Christoph Flamm (Universitaet
Wien, Austria) presented theoretical
background based on the graph-
coloring problem for the design of
RNA switches and an approach that
enables analysis of the kinetic beha-
vior of the RNA folding energy land-
scapes. The main focus of the
presentation was a computational
approach for the design of RNA
sequences that can fold into two or
more metastable secondary struc-
tures that can further be induced
to fold into one of the designed
conformations based on an external
trigger (e.g., temperature).61,62
Computational strategies that per-
mit the design of RNA nanoarchitec-
tures were detailed by Bruce Shapiro
(National Cancer Institute). He dis-
cussed novel strategies that predict
nucleotide sequences that can self-
assemble into3DRNAnanocomplexes
(also see http://www-ccrnp.ncifcrf.
gov/∼bshapiro/).34,38 Dr. Shapiro pre-
sented elements of a computational
RNA nanodesign pipeline,63,64 dis-
cussing the RNAJunction Database,19
NanoTiler,65 RNA2D3D algorithms,66
and RNA Dynamics,67,68 which are
used to build RNA nanoconstructs
that incorporate individual RNAmo-
tifs adhering to deﬁned user speci-
ﬁcations (Figure 3).69 Several of
the designed constructs, such as
nanocubes and hexagonal nano-
rings (Figure 3B,C), have been shown
to self-assemble in vitro and have
therapeutic potentials.34,38
A computational coarse-grained
approach for predicting RNA 3D
structure was presented by Nikolay
Dokholyan (University of North
Carolina). His group was able to
predict the native folding of large
RNA molecules by combining ex-
perimental and computational
approaches70,71 and also predicted
the folding of small RNAs using dis-
crete coarse-grained molecular dy-
namics (DMD).72,73
Irina Novokova from Neocles
Leontis's group (Bowling Green
State University) described a com-
bined experimental and modeling
approach for the assembly of tecto-
RNAs using pairs of GNRA loop/
loop-receptor interaction motifs.
Closed programmable assembled
complexes were shown to form di-
mers, trimers, and tetramers as well
Unlike DNA, RNA
molecules display
diverse structures
mediated by both
canonical and
noncanonical base
pairing and further
stabilized by tertiary
interactions,
pseudoknots, kissing
loops, stem stacking, etc.
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as open forms. Experimental evi-
dence supports the formation of
these complexes with high resis-
tance to nucleases.74 Additional
functionalities can be incorporated
in the helical regions, thus rendering
these nanocomplexes as potential
therapeutic delivery agents.
Rhiju Das (Stanford University)
made a case for a novel algorithm
for high-resolution 3D structure
modeling of RNA. He presented a
full-atom reﬁnement framework for
predicting and designing noncano-
nical RNA motifs that stabilize the
overall conformation via tertiary
interactions.75 He further presented
an alternative RNA modeling meth-
od, StepWise Ansatz (SWA), that can
identify noncanonical RNA motifs
and has the potential to characte-
rize conformation landscapes of this
complex biomolecule.
A novel computational method
wasdevelopedbySvetlanaShabalina's
group (National Institutes of Health,
Bethesda, USA) addressing a signiﬁ-
cant challenge in the RNAi ﬁeld,
namely, the prediction of eﬃcient
oligonucleotides for RNA interfer-
ence. The algorithm can design
and validate siRNA and shRNA
associated with high silencing eﬃ-
ciency, and targeted speciﬁcity can
be achieved by optimizing param-
eters such as terminal duplex
asymmetry and duplex stability.76
This novel approach considers the
predicted local secondary struc-
ture of the target and antisense
RNAs, and it is powerful enough for
genome-wide si/shRNA screening.
The program and numerous RNAi
experiments with various siRNA
and shRNA constructs are publicly
available at ftp://ftp.ncbi.nlm.nih.
gov/pub/shabalin/siRNA/si_shRNA_
selector/.
Figure 3. (A) Representation of part of the computational RNA nanodesign pipeline associated with NanoTiler.6365 What is
depicted is one result, ofmany,whichproduces a closed-ring structure generatedwith theNanoTiler software thatwas derived
in a totally automated fashion from a combinatorial search of motifs found in the RNAJunction database.19 Sequences that
were predicted for the shown structure were ultimately shown to be able to experimentally self-assemble into the depicted
form. Panel A adapted with permission from ref 65. Copyright 2008 Elsevier. (B) Depiction of 10 stranded RNA cubes that were
computer-designed with NanoTiler and later shown to be able to self-assemble.38,65 The layouts of the interacting strands are
shown on the right. It should also be noted that the 10 stranded cubes, as shown here, were assembled in three forms: without
a malachite green aptamer, with one malachite green aptamer, and with two malachite green aptamers. A properly formed
aptamer ﬂuoresces in the presence of a triarylmethane dye. The formation of the aptamers was used to conﬁrm the cubes' self-
assembly and designed functionalization. Panel B adapted with permission from ref 38. Copyright 2011 Nature Publishing
Group. (C) Depiction of the computer-designed, and later shown to be able to self-assemble, RNA hexagonal ring.34,68,69 Each
corner of the ring contains themotif derived from the RNAIi/RNAIIi kissing loop interaction that forms an angle of about 120,
which is conducive to hexagonal ring formation. Sides and dangling ends can be further functionalized. Panel C adapted from
ref 69. Copyright 2011 American Chemical Society.
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Finally, proteinRNA interactions
are common in protein synthesis,
binding transfer RNA (tRNA), and
ribosomal RNA (rRNA), as well as
binding messenger RNA (mRNA)
and small nuclear RNA (snRNA),which
are involved in RNA modiﬁcation.
Jarek Meller (University of Cincinnati)
discussed the potential of sequence-
based solvent accessibility prediction
for mapping RNA interaction sites in
proteins.
Biophysical and Single-Molecule Ap-
proaches in RNA Nanotechnology. RNA
as an intermediary molecule in the
complex cascade of gene expression
manifests diverse arrays of structures
and participates in numerous tertiary
interactions. To synthesize function-
ally relevant and deliverable RNA
nanoparticles, an understanding of
how RNA structures are formed and
stabilized via higher order second-
ary structure and tertiary interac-
tions is of paramount importance.
Single-molecule imaging of RNA
molecules is a powerful method that
can signiﬁcantly contribute to better
understanding of RNA structures,
their folding properties, and asso-
ciated interactions within the qua-
ternary complexes. Peixuan Guo
(University of Cincinnati) demon-
strated the utility of single-molecule
ﬂuorescence resonance energy
transfer (smFRET) in understanding
pRNA-based nanostructures. His
groupwas able to predict conforma-
tional changes of pRNA upon bind-
ing to the phage procapsid.77 Further-
more, the application of single-
molecule high-resolution imaging
with photobleaching (SHRImp)78 in
distancemeasurementsof twopRNAs
boundtoprocapsidwasalsodiscussed.
Elvin Aleman from David Rueda's
lab (Wayne State University) discussed
the use of 2-aminopurine (2AP), a
ﬂuorescent nucleotide, to study local
conformational changes using the sin-
gle-molecule approach. They devel-
oped a click-chemistry-based surface
immobilization approach79 to study
2AP ﬂuorescence dynamics when it is
incorporated in a ssDNA and a dsDNA.
This method can also be applied to
RNA.
Advances in single-particle track-
ing will serve as a promising tool in
DNA and RNA nanotechnology. Nils
Walter'sgroup (UniversityofMichigan),
in collaboration with Eric Winfree's
(Caltech), Hao Yan's (Arizona State
University), and Milan Stojanovic's
(Columbia University) laboratories,
developed experimental approaches
to study the molecular motion of
nucleic-acid-based nanoscale mole-
cular assemblies, called “spiders”,
using real-time single-particle ﬂuo-
rescence microscopy.80,81 They
were able to observe directional
motion of the molecular robot
along a 2D DNA origami substrate
(Figure 4).
Mass spectrometry (MS)-based
approaches are an elegant way to
characterize oligonucleotides, RNA-
mediated interactions, and eﬀects
of common ligands in these inter-
actions. Patrick Limbach's group
(University of Cincinnati) is applying
high-resolution, high-mass-accu-
racy MS to characterize oligonucleo-
tides and RNA-based nanoparticle
building blocks as a means for diag-
nostic applications and as a drug
development platform.82,83 Daniele
Fabris's group (State University of
New York, Albany) is also apply-
ing MS-based approaches to de-
cipher RNA structures and investi-
gate tertiary/quaternary interac-
tions and modulatory eﬀects of
small ligands as potential thera-
peutic targets.84
Scott Tenenbaum's group (State
University of New York, Albany) is
pioneering an RNA-based nano-
switch technology, called “structu-
rally interacting RNAs” (sxRNA) for
real-time detection of speciﬁc micro-
RNAs (miRNA) in cells; this technol-
ogy has tremendous potential to be
developed as a method in diagnos-
tics and therapeutics.
Meni Wanunu in Marija Drndic's
group (University of Pennsylvania),
in collaboration with New England
Biolabs, presented an electronic-de-
tection platform using synthetic
nanopores for detecting and quanti-
fying miRNA enriched from biologi-
cal tissue.85 This single-molecule
approach provides an attractive
low-cost alternative and, combined
with ultralow sample volumes (nL),
has the potential to exceed the de-
tection limits of conventional meth-
ods of microarray-based miRNA
proﬁling, ﬂuorescence, and radioac-
tive gel electrophoresis assays.
Nicolas Spinelli (Universite Joseph
Fourier, France) presented an ap-
proach to direct the assembly of
oligonucleotides into G-quadruplex
architectures (four-stranded struc-
ture of stacked guanine tetrads) using
a peptide scaﬀold. Surface plasma
resonance (SPR) was then used to
evaluate the aﬃnity, selectivity, and
binding mode of various ligands
with the immobilized G-quadruplex
complexes of various topologies,86
as ameans for screening viable drug
targets.87
Blaine Moore's group (University
of Oklahoma Health Sciences Center)
is working toward determining the
crystal structure of a fragment of
guide RNAs (gRNA) that are involved
in post-transcriptional editing of
mRNA (uridine insertion/deletion),
a requirement for the subsequent
expression of several mitochondrial
proteins. The results provide valu-
able insight on the conformation
and dynamics of the U-helix, which
is common among all gRNA/mRNA
duplexes and is a valuable drug
target.88
To synthesize
functionally relevant and
deliverable RNA
nanoparticles, an
understanding of how
RNA structures are
formed and stabilized via
higher order secondary
structure and tertiary
interactions is of
paramount importance.
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RNA Nanoparticle Assembly. Self-as-
sembly of RNA building blocks in a
predefined manner to form larger
multidimensional structures is a pro-
minent bottom-up approach and
represents an important means by
which biological techniques and
biomacromolecules can be success-
fully integrated into nanotechnol-
ogy.32,89,90 Within the realm of
self-assembly, there are two main
subcategories: templated and non-
templated assembly. Templated as-
sembly involves the interaction of
RNAs with one another under the
influence of a specific external force,
structure, or spatial constraint. RNA
transcription, hybridization, replica-
tion, molding, and phi29 pRNA hex-
americ ring formation are within this
category. Nontemplated assembly
involves the formation of a larger
structure by individual components
without any external influence. Ex-
amples include ligation, chemical
conjugation, covalent linkages, loop/
loop interactions of RNA such as the
HIV kissing loop, and phi29 pRNA
dimer or trimer formation.25,32,33,89,90
Natural RNA molecules form
unique and intriguingmultimers with
special functionalities. Examples in-
clude retroviral kissing loops that
facilitate dimerization,91,92 pRNA
of the bacteriophage phi29 DNA
packaging motor that assembles
into dimers and hexamers via hand-
in-hand interactions between right-
and left-interlocking loops,21 and
bicoid mRNA of Drosophila embryos
that form dimers via hand-in-arm
interactions.93 In addition, numer-
ous RNA molecules contain motifs
with ﬁxed structure and tightly
folded domains. These natural prop-
erties have been utilized to assem-
ble varieties of RNA nanoparticles
with diverse biological properties
and wide-ranging functions.
Peixuan Guo's group (University
of Cincinnati) reported the construc-
tion of chemically modiﬁed stable
pRNA-based nanoparticles that
were RNase-resistant, while retain-
ing their biological activity in pro-
capsid binding and gearing the
phi29 DNA packaging motor.24 He
further demonstrated the scale-up
synthesis of stable RNA nanoparti-
cles greater than 100 nt,94 which
overcomes the limitation of cur-
rently available commercial synth-
esis of RNA oligonulceotides (up to
80 nt with low yield). His group
generated bipartite chimeric pRNA
constructs that can assemble into
the full-length functional pRNA,
while retaining their biological activ-
ity and proﬁciency for incorporating
therapeutic and diagnostic modules.
RNA aptamers are a class of
oligonucleotides that can recog-
nize speciﬁc ligands through the
formation of binding pockets.9597
SELEX is typically used to screen
for the aptamers from randomized
RNA pools.95,96,98 Chaoping Chen
(Colorado State University) has been
developing innovative approaches
to tackle Flaviviral infections includ-
ing Dengue, West Nile, and Yellow
Fever, for which there are no eﬀec-
tive therapeutics currently available.
Using SELEX, her group was able
to identify RNA aptamers that were
found to bind with RNA-capping
enzymes of Flaviviruses. Using in vitro
and in vivo experiments, she demon-
strated the therapeutic potential of
novel tRNAaptamer fusions in treat-
ment of viral infections. In related
work, Hua Shi (State University of
New York, Albany) discussed bot-
tom-up approaches that utilize RNA
aptamers to construct protein-like
molecules with predetermined func-
tions.99,100
Porphyrin macrocycles have been
studied for their roles in oxygen
transport in blood andphotosynthe-
sis. By virtue of porphines' inter-
action with light, this class of
molecules has been exploited in
medicine. Magnus Bergkvist (State
University of New York, Albany) pre-
sented work demonstrating the
oligonucleotide-mediated packag-
ing of photoactive porphyrin into
bacteriophage MS2 capsid. His
group has been working on virion-
derived nanocontainers that are
capable of delivering nonviral RNA/
DNA for therapeutics.
RNA Nanoparticles in Therapeutics.
Over the past decade, RNA-based
therapeutics have been investigated
extensively for treatment and detec-
tion of cancer, viral ailments, and
genetic diseases. Several natural
and synthetic RNA molecules are
being actively pursued, including,
but not limited to (1) design and
construction of antisense and siRNA
for silencing genes with high effi-
ciency and specificity; (2) assembly
of multivalent RNA nanoparticles
with receptor-binding aptamers for
targeted delivery; (3) incorporation
of ribozymes for intercepting and
Figure 4. Watching the movement of single-molecular spiders at super-resolution (Nils Walter group). A multi-legged
molecular nanoassembly walks along a prescribed substrate track on a DNA origami (A), where its ﬂuorophore label (F1) is
tracked at super-resolution relative to a label on the end of the track (F2) by total internal reﬂection ﬂuorescence (TIRF)
microscopy (B).80,81 The resulting trajectory compares well with a scale-drawn schematic of the origami (C). Figure modiﬁed
with permission from ref 81. Copyright 2010 Elsevier.
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cleaving target RNA substrates; and
(4) conjugation of drugs and chemi-
cal ligands for therapy and detection.
Ningsheng Shao's group (Beijing
Institute of Basic Medical Sciences,
China) is developing a wide range of
SELEX techniques for identifying tu-
mor markers as a means for early
diagnosis and therapy. Subtractive
cell SELEX procedure, developed in
his lab in 2003, can select aptamers
that can distinguish diﬀerentiated
cells (e.g., carcinoma cells) from un-
diﬀerentiated epithelial cells.101 A
similar strategy, using whole-bacter-
ium-based SELEX, can select ssDNA
aptamers for detection of patho-
gens, such as the Staphylococcus
aureus.102 The group has also devel-
oped an in situ tissue-slide-based
SELEX method that can select for
aptamers speciﬁc to all tissue frac-
tions (such as extracellular matrix,
membrane components, and intra-
cellular targets) and can distinguish
cancer cells from normal cells in
clinical specimens.103
Jean-Jacques Toulme (Universite
de Bordeaux, France) presented
work on a novel aptamer identiﬁed
via SELEX that folds into a hairpin
structure and can target viral RNA
(HIV and HCV) structural elements
by forming stable kissing com-
plexes.104 Such a kissing aptamer
targeted to the trans-activating re-
sponsive (TAR) element of HIV-1 dis-
played both high aﬃnity and ex-
quisite speciﬁcity (Figure 5). RNA
aptamers produced in situ in HeLaP4
cells from an expression vector in-
hibit TAR-dependent expression of a
reporter gene. Chemically modiﬁed
aptamers also reduce TAR-depen-
dent expression upon transfection
of recipient cells.
RNA interference (RNAi)-based
therapeutics using siRNA have the
potential to silence disease-causing
genes. However, signiﬁcant chal-
lenges remain, especially with re-
gard to in vivo delivery of siRNA.
Muthiah Manoharan (Alnylam Phar-
maceutical, USA) delineated the
prospects of novel lipid-like nano-
particles (LNP) mediated in vivo de-
livery of RNAi therapeutics.105 He
also discussed the potential of che-
mically modiﬁed RNA and various
siRNA-based therapeutics currently
in clinical trials or under develop-
ment. Likewise, Weikang Tao (Merck
Research Laboratories, USA) pre-
sented current work on in vivo siRNA
therapeutics, their potential toxici-
ties, and therapeutic eﬃcacies. He
provided guidance on how to opti-
mize the development of LNP-for-
mulated siRNA for therapeutics and
ways to minimize immuno-stimula-
tory activities for improving their
safety proﬁles.106
Thomas Hermann's (University of
California, San Diego) group has
characterized a new RNA drug tar-
get in the hepatitis C virus's internal
ribosome entry site (IRES) and estab-
lished a conformational mechanism
of action for a small molecule inhi-
bitor that binds to this RNA.107
He was able to obtain the crystal
structure at 2.2 Å resolution of a
square-shaped, double-stranded RNA
construct derived from HCV IRES
domain. He also presented a novel
supramolecular approach for cellu-
lar delivery of siRNAs using a spe-
cially designed β-cyclodextrin peptide
conjugate, which acts as a ligand for
complex formationwith theRNA (RGO
Biosciences LLC).
Use of multimerized siRNA con-
jugate complexes for cell delivery
Figure 5. Complex between the trans-activating responsive RNA element TAR, viral (Tat), and cell proteins (cyclin T1, CDK-9) is
required for eﬃcient transcription of the HIV-1 genome. Disruption of this complex leads to abortive transcription of the
retroviral DNA. A high-aﬃnity RNA hairpin aptamer (R06) speciﬁcally recognizes TAR. The transcription of a R06 construct in
recipient cells reduces the production of β-galactosidase whose expression is driven by the HIV-1 promoter containing TAR, in
response to retroviral infection. Therefore, targeting RNA hairpins oﬀers an alternative to targeting proteins for the design of
artiﬁcial modulators of gene expression.
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and gene silencing was presented
by Tae Gwan Park (Korea Advanced
Institute of Science and Technology,
South Korea). He reviewed the use of
charged cationic polymers, lipids,
and peptides for intracellular deliv-
ery of siRNAs. He also presented
work from his laboratory focused
on the development and delivery
of self-cross-linked and multimer-
ized siRNAs via cleavable chemical
linkages. Eﬃcacy of these multimer-
ized siRNAs in gene silencing with-
out invoking immune induction was
presented.108
Dong-Ki Lee's group (Sungkyunkwan
University, South Korea) presentedpro-
misingnewresultsonthedevelopment
of a branched RNA duplex structure
that has the potential to target and to
silence multiple genes implicated in
cancer cell proliferation and survival.109
Henry Li (Kylin Therapeutics,
USA) presented compelling evi-
dence on the therapeutic prospects
of pRNA-based RNA nanoparticles.
pRNA nanoparticles have a deﬁned
structure (modular design that en-
ables multiple functionalities), are
thermodynamically and metaboli-
cally stable, have an optimum dia-
meter of 1050 nm, and display
superior in vivo pharmacological
proﬁles.110 Malak Kotb's group
(University of Cincinnati) is using
pRNA as a scaﬀold for constructing
chimeric pRNA-siRNA-CD4 aptamer
nanoparticles to block the growth of
lymphocytic leukemia and lympho-
ma cells without aﬀecting the survi-
val of normal lymphocytes.
John Rossi (Beckman Research
Institute, USA) presented an elegant
study in which three endogenous
targets were silenced by siRNA cock-
tails in both in vitro cell cultures and
in vivo animal models. This ap-
proach utilized a combination of
siRNAs targeting expression of host
and viral genes. Dr. Rossi's research
demonstrates that siRNAs are able
to inhibit HIV replication in a huma-
nized HSC-CD34 mouse model and
prevent HIV-mediated T-cell deple-
tion characteristic of AIDS.111,112 Mei
Zhang (Case Western Reserve Uni-
versity, USA) also presented the
eﬃcacy of siRNA-mediated inhibition
of mammary tumor growth and
metastasis in a 4T1 mouse model.
Numerous proteins are associated
with innate immunity (initial immune
response to pathogens), including
RNA-activated protein kinase (PKR).
These classes of proteins have the
ability to discriminate self-RNA from
foreign, pathogenic RNA via patho-
gen-associatedmolecular patterns.113
Philip Bevilacqua's group (Pennsyl-
vania State University) is developing
mRNA-based therapeutics by design-
ing nucleoside modiﬁcations for reg-
ulating the activity of PKR.114
RNA Chemistry for Nanoparticle Synthe-
sis, Conjugation, and Labeling. For the
field of RNA nanotechnology and
therapeutics, it is vital to develop
efficient methods for (1) preparing
large amounts of pure RNA oligonu-
cleotide sequences and (2) incorpor-
ating a large diversity of conjugates
and labels for functionalizing and
probing the RNA construct at specific
positions. Fundamentally, RNA oligo-
nucleotides can be prepared by
either enzymatic transcription reac-
tions or automated solid-phase
synthesis. Enzymatic approaches
can provide access to relatively
long transcripts in significant quan-
tities; however, their outcome is
frequently sequence-dependent.
The heterogeneity of the 30-end
has been an issue,115 which can be
addressed by extending the tran-
scribed sequence beyond the in-
tended end and then cleaving
the RNA at the desired site using
ribozymes, DNAzymes, or RNase
H.115117 Transcription reactions
are also limited in their ability to
furnish labeled or sequence specifi-
cally modified RNA transcripts. To
meet this challenge, GMP or AMP
derivatives, which can only be used
for transcription initiation but not
for chain elongation, have been
used. Fluorescent RNA can also be
easily synthesized in vitro with T7
RNA polymerase using a new agent
tCTP.118 To generate longer RNA,
two short, synthetic RNA fragments
can be further ligated using RNase
ligase II or T4 DNA ligases.116
Standard solid-phase phosphor-
amidite chemistry for the synthesis
of DNA and RNA oligonucleotides
has advanced signiﬁcantly in recent
years, particularly when it comes to
the synthesis of relatively long RNA
oligonucleotides.119,120 In addition
to “classical” approaches relying on
the tert-butyldimethylsiloxy (TBDMS)
protecting group for the 20-hydroxyl,
which were somewhat limited in
their ability to provide rather long
sequences, two “modern” approach-
es have been introduced for
RNA synthesis: (1) the 50-O-DMT-
20-O-[(trisisopropylsilyl)oxy]methyl
(20-O-TOM) protecting scheme de-
veloped by Pitsch,121 and (2) the 50-
O-silyl-20-O-orthoester (20-ACE) pro-
tecting group combination, intro-
duced by Scaringe and Caruthers.122
These protection schemes facilitate
the synthesis of labeled and mod-
iﬁed RNA oligonucleotides for di-
verse applications. However, chal-
lenges remain when it comes to
the preparation and incorporation
of novel nucleosides, linkers, and
labels, as their compatibility with
current synthetic and protection
schemes needs to be empirically
determined.
Natural RNA is sensitive to RNase
and is especially unstable in serum.
The relative instability of RNA has
long hindered its application as a
construction material. Improve-
ments in RNA stability have pro-
gressed rapidly, including (1)
chemical modiﬁcation of the base
(e.g., 5-Br-Ura and 5-I-Ura); (2) mod-
iﬁcation of the phosphate linkages
(e.g., phosphothioate, boranophos-
phate); (3) C20 (e.g., 20-ﬂuorine, 20-O-
methyl or 20-amine);123 (4) peptide
nucleic acids (PNA), locked nucleic
acids (LNA) and derivatives;124,125 (5)
30-end-capping;126 and use of cross-
linking agents (psoralen, nitrogen
mustard derivatives, and transition
metal compounds).127 Adam Mazur
(Girindus America Inc., USA) dis-
cussed the commercial availability
of a wide variety of these chemically
modiﬁed RNAs and their advan-
tages in RNA-based therapeutics.
He also discussed the challenges in
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manufacturing processes, from op-
timizing small-scale sequence-direc-
ted synthesis to puriﬁcation schemes
and large-scale production of the
oligonucleotides.
In probing and monitoring the
structure and structural changes of
RNA nanoconstructs and therapeu-
tics, the use of external and/or inter-
nal ﬂuorescence reporter molecules
(Figure 6) is frequently central. Fluo-
rescent labels are also important for
detecting and determining the
strength of the interaction between
RNA and, for example, other macro-
molecules and ligands. There is con-
tinuous development of this group
of reporter molecules and a rapidly
growing subgroup is the ﬂuorescent
nucleic acid base analogues. Marcus
Wilhelmsson (Chalmers University
of Technology, Sweden) discussed
the advantage of ﬂuorescent ana-
logues of the tricyclic cytosine
family128,129 in calculating accurate
distances and orientation changes
in nucleic acid systems using FRET.130
Since nucleic acids are practically
nonﬂuorescent in nature, artiﬁcial
ﬂuorescent base analogues are im-
portant for investigating DNA or
RNA systems. Fluorescent base ana-
logues are morphologically similar
to natural nucleobases and have the
ability to form hydrogen bonds with
a natural nucleobase in the comple-
mentary strand. Furthermore, these
artiﬁcial bases retain the structure of
DNA (or RNA) and can be incorpo-
rated internally and therefore have
an advantage over covalently at-
tached end-labeled dyes (ﬂuorescein,
rhodamines, Cy or Alexa dyes).
Yitzhak Tor's group (University of
California, San Diego) is working on
RNA folding and RNA drug binding.
He discussed the design, synthesis,
and incorporation of novel ﬂuorescent
nucleobase analogues and described
the advantages in developing ﬂuo-
rescence-based discovery and detec-
tion systems.131133 For diﬀerent
classes of ﬂuorophores, their charac-
teristic proﬁles, and applications, see
recent reviews.134,135
Funding Opportunities in Nanotechnol-
ogy for Therapeutics. Sara Hook
(National Cancer Institute, USA) pre-
sented the tremendous resources
and infrastructure available through
the Alliance for Nanotechnology in
Cancer established by the National
Cancer Institute (NCI) to support
cancer-relevant nanotechnology
endeavors. She described how the
alliance supports interdisciplinary
research efforts between biologists,
clinicians, and physical scientists
with the goal of advancing preven-
tion, diagnosis, and treatment efforts.
The NCI alliance will continue to
support collaborations by providing
infrastructure as well as research and
training grants for establishing a di-
verse portfolio of new technologies
supporting a range of applications.
In addition, several centers of cancer
nanotechnology across the United
States will be established. Detailed
information regarding the NCI sup-
ported Alliance for Nanotechnology
in Cancer and other funding oppor-
tunities is available at the NCI Web
site (http://nano.cancer.gov). A fully
equipped Nanotechnology Char-
acterization Laboratory (http://ncl.
cancer.gov) is also available for
characterizing potential therapeutic
nanoparticles, such as their physical
attributes (e.g., size, shape, surface
chemistry, and solubility), in vitro bio-
logical properties (e.g., pharmacology
and cytotoxicity), and in vivo compat-
ibility assays (e.g., efficacy and safety).
At present, the challenging areas in-
clude molecular imaging and early
detection (high spatial and temporal
resolution, aswell as sensitivity), in vivo
nanotechnology imaging systems
(minimal or noninvasive methods),
and multifunctional therapeutics,
especially with regard to cancers
with low survival rates such as brain,
lung, pancreas, and ovarian cancers.
FUTURE OUTLOOK
Signiﬁcant challenges remain
with regard to delivery of RNA-
based nanoparticles. From a com-
mercial perspective, the manufac-
turing process can be complex and
inconsistent. The production/synth-
esis of oligonucleotides with func-
tional moieties has to be a scalable
Figure 6. (A) Internal nucleic acid reporter group, represented here by the ﬂuorescent base analogue tC in pair with guanine
looking down the long axis of a DNA duplex. (B) Same internal reporter group looking along the short axis of a DNA duplex.
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process (chemically). The RNA nano-
scaﬀold has to retain its folding pro-
perties and display a stable nature.
The RNA construct needs to have a
modular design, such that the com-
plex can be self-assembled from the
basic building blocks. Moreover, the
cost ofmanufacturing and associated
analytical characterizations of nano-
particles needs to be reasonable.
From a structural point of view,
there are concerns over the stoichi-
ometry and particle size, robustness
of functional modules, and stability
(thermodynamic, chemical, and meta-
bolic) of the RNA nanoparticles. Ef-
fective computational approaches ac-
counting for noncanonical base
pairing, long-range tertiary interac-
tions, and equilibrium folding of the
ﬁnal complex are in great demand for
the design and construction of RNA
nanoparticles (using interacting, archi-
tectural, and ligand-binding motifs)
with functional modalities (therapeu-
tic, targeting, anddiagnostic). Theﬂexi-
bility of RNAmolecules and unpredict-
ability of RNA folding presents a
challenge for simulationandmodeling.
From an in vivo delivery point of
view, the nanoparticles need to dis-
play favorable pharmacological pro-
ﬁles, biodistribution, pharmokinetic
proﬁles, minimum immunogenicity,
relatively high eﬃciency of disease
tissue/cell targeting, and remain in-
tact at extremely low concentra-
tions. Furthermore, the RNAi-based
therapeutics need to be internalized
by the target cell and escape from
the endosomes if they enter via
receptor-mediated endocytosis. En-
dosomal escape for release of the
therapeutic nanoparticles remains a
challenge in the ﬁeld.
As outlined in this Nano Focus
article, several groups have made
signiﬁcant strides with regard to
aptamer- and dendrimer-based de-
livery approaches to therapeutic
RNAs. Combinatorial therapy using
aptamers and siRNA has proved use-
ful for achieving maximal eﬃciency
and eﬃcacy in targeting. In addition,
structural and functional aspects of
RNA nanoparticles have made rapid
progresswith respect to their design
and delivery. Finally, chemical label-
ing of RNA using ﬂuorescent analo-
gues has progressed remarkably.
The meeting highlighted current re-
search and future prospects of RNA
nanotechnology. Applications and
the impact of RNA nanotechnology
in the assembly and delivery of
siRNAs, pRNA, therapeutic ribozymes,
RNA aptamers, and riboswitches are
becoming a reality. RNA nanotech-
nology is already making a signiﬁ-
cant impact in drug delivery and
therapeutics as many siRNA-based
products are in the pipeline for po-
tential treatment of respiratory
synchitial viral infections, hepatitis
C virus, liver cancer, and Hunting-
ton's Disease. Collaborative endea-
vors between academia, government,
and industry are likely necessary to
advance RNA nanotechnology into a
practical tool for drug discovery and
delivery in the near future.
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